BostonSP

Boston Strategic Partners (BSP) is a global health industry consulting firm with expertise in HEOR, RWE analytics, MedComms and Business and Clinical Strategy

[BostonSP @BostonSP]

Boston Strategic Partners (@BostonSP) is a global life sciences consulting firm with five main practice areas: 1)business and clinical strategy, 2)financial advisory, 3)regulatory strategy, 4)health economics and outcomes research, and 5)medical and technical communications 1/2

[BostonSP @BostonSP]

We extend our heartfelt appreciation to their families, as well as to the veterans and active-duty military members within our community and beyond.

Wishing you and your family a safe, peaceful, and meaningful Memorial Day weekend. 🇺🇸

#MemorialDay #RememberAndHonor

[BostonSP @BostonSP]

Today, Boston Strategic Partners remembers the brave servicemen and women who made the ultimate sacrifice in service to our country. Their courage serves as a profound reminder of the price of our freedom, and we honor their legacy with gratitude.

[BostonSP @BostonSP]

“Efficacy of Panitumumab vs. Cetuximab Plus Chemotherapy in Recurrent or Metastatic Squamous-Cell Carcinoma of the Head and Neck: An Anchored Matching-Adjusted Indirect Comparison”

https://t.co/Mn8KRo949U

[BostonSP @BostonSP]

What an incredible week at #ISPOR2026 (@ISPORorg)! The @BostonSP team -- Kunal Lodaya, MD, @hyatt101, and Jonathan Lilley-- loved connecting with industry leaders, engaging in thought-provoking sessions, and hearing new perspectives in the #HEOR community.

[BostonSP @BostonSP]

“Addressing Missing Data and Confounding in Acute Kidney Injury Risk Comparison Between Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention Using Multiple Imputation and Propensity Score Matching” https://t.co/ljAznNvP2v

[BostonSP @BostonSP]

Stop by our poster to chat with Jonathan Lilley and learn how our analysis addresses clinical evidence gaps for targeted therapies in oncology!

#ISPORAnnual #RWD #HEOR

[BostonSP @BostonSP]

Our poster presentation at #ISPOR2026 addresses the lack of head-to-head randomized trials between panitumumab and cetuximab for patients receiving chemotherapy for recurrent or metastatic squamous-cell carcinoma of the head and neck.

[BostonSP @BostonSP]

Clinical implications:
These data provide crucial evidence for future health technology assessment decision-making

[BostonSP @BostonSP]

Stop by our poster, presented by Kunal Lodaya, MD, to learn more about how we leveraged real-world data to address missingness and confounding in this high-risk patient population!

#ISPORAnnual #RWD #HEOR

[BostonSP @BostonSP]

Our poster presentation at #ISPOR2026 compares the risk of acute kidney injury (AKI) between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI).

[BostonSP @BostonSP]

Clinical implications:
These robust results provide clinicians with critical comparative effectiveness data to help navigate revascularization decisions for patients with coronary artery disease

[BostonSP @BostonSP]

When: Monday, May 18th, from 10:30 AM – 1:30 PM

Presented by: Kunal Lodaya, MD and Jonathan Lilley

Drop us a comment below or find us during the conference – we’d love to discuss more with you!

#ISPORAnnual #RWD #MedicalCommunications #HEOR

[BostonSP @BostonSP]

Headed to #ISPOR2026? Don’t forget to stop by our poster presentations!

We’re excited to share two topics on Monday:

[BostonSP @BostonSP]

Poster CO31: Efficacy of panitumumab vs. cetuximab plus chemotherapy in recurrent or metastatic squamous-cell carcinoma of the head and neck: An anchored matching-adjusted indirect comparison.